Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8008714 | 0.88 | CYP1A2 (0.52) | CCNA2CDK2CCNA1CYP1A2HSP90AA1 | |
| SCHEMBL28221808 | 0.86 | CCNA2 (0.41) | CCNA2CDK2CCNA1CYP1A2HSP90AA1 | |
| SCHEMBL16828162 | 0.78 | CCNA2 (0.50) | CCNA2CDK2CCNA1 | |
| SCHEMBL9432184 | 0.78 | CYP1A2 (0.61) | CYP1A2MAPTGAASMN1; SMN2PDCD1LG2 | |
| SCHEMBL11059135 | 0.77 | CCNA2 (0.46) | CCNA2CDK2CCNA1CYP1A2HSP90AA1 | |
| SCHEMBL30559673 | 0.77 | CCNA2 (0.46) | CCNA2CDK2CCNA1CYP1A2HSP90AA1 | |
| SCHEMBL26977474 | 0.77 | CCNA2 (0.46) | CCNA2CDK2CCNA1CYP1A2HSP90AA1 | |
| SCHEMBL10617813 | 0.76 | CCNA2 (0.48) | CCNA2CDK2CCNA1HSP90AA1HSP90AB1 | |
| SCHEMBL30721418 | 0.76 | CCNA2 (0.48) | CCNA2CDK2CCNA1HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL16828222 | 0.76 | CCNA2 (0.48) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6087500-A | Methods for producing pyrimidine compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | claimed |
| EP-0902019-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-03-17 | — | — | EP | claimed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| CN-116829550-A | Pyrimidine-2-ylsulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-0902019-A4 | PROCESSES FOR THE PREPARATION OF PYRIMIDINE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-6087500-A | Methods for producing pyrimidine compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| US-6087500-A | Methods for producing pyrimidine compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0902019-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-03-17 | — | — | EP | disclosed |
| EP-0902019-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043265-A1 | PROCESSES FOR THE PREPARATION OF PYRIMIDINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | CCNA2 2260/4885CDK2 1005/4885CCNA1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.